

LANXESS – Commerzbank/Oddo BHF Corporate Conference 2022

Delivering operationally and executing on key strategic milestones

Safe harbor statement

The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.

This presentation contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Agenda

- 1 LANXESS today**
- 2 Q2 review and financials**
- 3 Proactively managing risks**
- 4 Growth opportunities**
- 5 Recent portfolio changes**

Reduction of complexity through portfolio changes leading to a new segment structure



Monetization of BU HPM stake with attractive financials

| BU HPM Sales EBITDA pre | Multiple | Enterprise value | Use of proceeds |
|----------------------------|----------|---|---|
| ~€1.5 bn* ~€210 m* | 12x | ~€2.5 bn Thereof cash proceeds of ≥€1.1 bn from first payment** | De- leveraging share buyback planned |


LANXESS entitled to receive a total of ~€2.5 bn in value; not yet reflected in market perceptions

LANXESS profile improves: more resilient, less complex, lower leverage, better ESG footprint



Higher resilience

Auto exposure




- Exposure to volatile auto industry significantly reduced
- Specialty character increased



Lower complexity

Number of Segments




- Clear focus on Specialty Additives and Consumer protection
- Reduced asset base in Europe leads to more balanced global production footprint



Improved financial profile

Leverage* incl. IFF MC




- Proceeds used for leverage reduction
- Moving towards 2.5x net financial debt / EBITDA



Improved sustainability

CO₂ emissions



- Engineering materials production is energy and CO₂ intensive (esp. nitrous oxide)
- Transfer of business reduces CO₂ footprint significantly

Strong portfolio of attractive businesses: Reduced complexity, higher margins, asset lighter

Advanced Intermediates



- Advanced Industrial Intermediates
- Inorganic Pigments



- Among top 3 players
- Cost, technology and process leadership

Specialty Additives



- Lubricant Additives Business
- Polymer Additives
- Rhein Chemie



- Among top 3 players
- Small volume, high impact
- Integrated value chains

Consumer Protection



- Flavors & Fragrances
- Liquid Purification Technologies
- Material Protection Products
- Saltigo



- # 1-3 positions
- Attractive secular growth
- Strong margins
- Asset light & high cash conversion

Executing on our strategy: Portfolio transformation strengthens our resilience and competitiveness

Higher
resilience

 **Reducing cyclical market exposure and becoming more resilient**

- ✓ Underperforming businesses divested – 6 transactions
- ✓ Acquisitions in the area of Consumer Protection – 5 transactions

Less than 10% Auto exposure*


Global
footprint

 **Strengthening global sales with focus on Americas**

- ✓ Acquisitions reduce German production footprint
- ✓ More balanced and optimized sales split

Increase in US sales exposure


Improving
financial
profile

 **Upgrading financial profile with focus on de-leverage and cash flow improvement**

- ✓ Leverage addressed with sale of HPM
- Managing the controllables

Commitment to solid investment grade

Recent portfolio measures lead to a more balanced end-market exposure



- 1. **Mobility exposure reduction**
 - ✓ Total exit from leather
 - ✓ Sale of HPM business
- 2. **Higher portion of end-consumer focused markets**
 - ✓ Full contribution of recent acquisitions
 - ✓ Growth above GDP in Consumer Protection

We have defined clear focus topics and objectives – aligned with societal goals and our strategic ambition



Objectives*

- LANXESS to become climate neutral by 2040, -50% CO₂e emissions by 2030 versus 2018
- LTIFR** reduction of 50% to 1.0 in 2025 vs. 2016
- Increase proportion of women in management to 30% by 2030
- Reduction of absolute water withdrawal by 15% at water risk sites by 2023
- Increase in energy efficiency of 40% to < 1.24 (MWh/t) compared to base year 2015

Ambition: LANXESS as a leading, resilient, sustainable, and profitable company

* Selection **LTIFR: Lost time injury frequency rate


LANXESS enhances climate strategy by adding Scope 3 reduction target and gaining SBTi approval

Net Zero \ Value Chain

- Newly set Scope 3 emission reduction target
- Approved by SBTi



LANXESS Scope 3 emissions pathway



LANXESS climate strategy

2019: “Climate Neutral 2040” with roadmap for Scope 1+2 emissions reduction


- Realize major impact projects for climate protection
- Decouple emissions and growth
- Pursue technological innovations

2022: “Net Zero Value Chain” strategy to reduce Scope 3 value chain emissions

- Use of sustainable raw materials
- Transition to green logistics
- Increasingly offer low-carbon and climate-neutral products


Leading ESG rating providers honor our performance

MSCI
ESG RATINGS



Convincing climate strategy
Ongoing improvement: Water
Stress & Chemical Safety

ISS ESG



Prime status
Top 8%


CDP
DISCLOSURE INSIGHT ACTION



Climate leader
Top 5%

Dow Jones
Sustainability Indices

Powered by the S&P Global CSA




Top 10% in DJSI World
(11th year)
DJSI Europe (5th year)

LANXESS' performance is also recognized by further ESG indices and rating providers



Comparing valuation pre and post deal points to underappreciated transformation


in € m,
illustrative



Multiple decreases to only 3.8x EV/ EBITDA after exit from HPM showcases valuation gap

In a nutshell: Five of the most striking reasons to invest

- 1 Embark on an exciting transformation journey to high margin specialty chemicals businesses
- 2 Unique specialty chemicals portfolio with leading market positions
- 3 Proven resilient business model – with many growth options
- 4 Forerunner in sustainability – awarded by leading rating agencies
- 5 Energizing chemistry – committed management team embedded in performance oriented corporate culture




Agenda

- 1 LANXESS today
- 2 Q2 review and financials
- 3 Proactively managing risks
- 4 Growth opportunities
- 5 Recent portfolio changes

Q2 2022: Guidance achieved

Increased earnings

EBITDA pre



Financial Highlights

**+36%
Sales
increase**


full pass-through of
inflated raw material
and energy costs

Logistic issues held
back volumes

**+14%
EBITDA
pre**


to €253 m,
top line inflation
weighs on margin

Guidance for FY 2022 confirmed, based on current market data




Current view on economy

- Continuously high level of energy and raw material costs
- Ongoing disruptions in global supply chains and logistic constraints
- Increasing pressure from general inflation on global demand



LANXESS EBITDA pre outlook*



Q2 2022: Next strategic steps towards specialty chemicals executed

Highlights and challenges

- ✓ Acquisition of IFF's microbial control: closed on 1st July
- ✓ A leading global JV for high performance engineering polymers agreed with Advent (HPM team up with DSM)
- ✓ Reduction of complexity through portfolio changes (leading to a new segment structure)
- ✓ Strong growth in Specialty Additives and Consumer Protection
- ✓ SBTi approved 1.5° climate path and Scope 3 targets
- 🚧 Ongoing logistic constraints held back volumes
- 🚧 Inflationary environment continues

LANXESS Group: Further increase in EBITDA pre

Full pass-through of input costs


Price **+26%** Volume **-6%** FX **+7%** Portfolio **+9%**

Total **+36%**

Q2 Sales vs. PY

| [€ m] | Q2/2021 | Q2/2022 | Δ | 1H 2021 | 1H 2022 | Δ |
|------------|---------|---------|-----|---------|---------|-----|
| Sales | 1,469 | 1,999 | 36% | 2,841 | 3,930 | 38% |
| EBITDA pre | 221 | 253 | 14% | 414 | 515 | 24% |
| Margin | 15.0% | 12.7% | | 14.6% | 13.1% | |
| CAPEX | 82 | 92 | 12% | 143 | 151 | 6% |

- Significant sales increase in all segments driven by continued successful pass-through of higher raw material and energy prices, additionally supported by portfolio and FX
- Higher EBITDA pre results from strong contribution of Specialty Additives and Consumer Protection; logistic constraints held back volumes
- Full pass-through of inflated input costs and lower volumes impacted margins



Advanced Intermediates: Soft result despite price pass-through

Volumes held back by various logistic limitations


| [€ m] | Q2/2021 | Q2/2022 | Δ | 1H 2021 | 1H 2022 | Δ |
|------------|---------|---------|------|---------|---------|------|
| Sales | 466 | 587 | 26% | 918 | 1,200 | 31% |
| EBITDA pre | 91 | 74 | -19% | 161 | 161 | 0% |
| Margin | 19.5% | 12.6% | | 17.5% | 13.4% | |
| CAPEX | 28 | 19 | -32% | 48 | 37 | -23% |

Price **+29%** Volume **-8%** FX **+5%** Portfolio **0%**

Total **+26%**

Q2 Sales vs. PY

- Sales increase driven by higher prices due to raw material and energy price pass-through in both BUs, positive FX
- Logistic constraints burden volumes especially in BU IPG
- EBITDA pre and margin impacted by time lag in price pass-through and lower utilization on planned maintenance turnarounds in BU All



Specialty Additives: Earnings benefit from continued price catch-up

All BUs contribute, BU PLA delivers especially well

| [€ m] | Q2/2021 | Q2/2022 | Δ | 1H 2021 | 1H 2022 | Δ |
|------------|---------|---------|-----|---------|---------|-----|
| Sales | 568 | 764 | 35% | 1,085 | 1,494 | 38% |
| EBITDA pre | 89 | 134 | 51% | 163 | 270 | 66% |
| Margin | 15.7% | 17.5% | | 15.0% | 18.1% | |
| CAPEX | 24 | 24 | 0% | 40 | 37 | -8% |

Price **+26%** Volume **-5%** FX **+10%** Portfolio **+4%**

Total **+35%**

Q2 Sales vs. PY

- Improved sales in all BUs, driven by strong pricing and FX
- Volumes remain on high level compared to strong previous year base but continuously held back by logistic constraints
- Ongoing recovery in aviation and oil & gas industry
- Continued price catch-up and positive FX development supports EBITDA pre and margin increase



Consumer Protection: Portfolio effect shapes results

BU F&F integration well on track

Price **+22%** Volume **-5%** FX **+4%** Portfolio **+31%**

Total **+52%**

Q2 Sales vs. PY

| [€ m] | Q2/2021 | Q2/2022 | Δ | 1H 2021 | 1H 2022 | Δ |
|------------|---------|---------|------|---------|---------|-----|
| Sales | 366 | 558 | 52% | 707 | 1,064 | 50% |
| EBITDA pre | 71 | 90 | 27% | 147 | 176 | 20% |
| Margin | 19.4% | 16.1% | | 20.8% | 16.5% | |
| CAPEX | 16 | 36 | 125% | 30 | 59 | 97% |


- Significant sales increase due to portfolio, successful pricing and FX
- Volumes impacted by logistic challenges
- Increased EBITDA pre due to successful pricing and contribution from acquired EKC business
- Margin held back by lower volumes and energy price driven top line inflation

P&L Q2: Successful pass-through of higher input costs - ongoing logistic constraints and lower volumes burden

| [€ m]* | Q2/2021 | | Q2/2022 | | yoy in % |
|---------------------------|----------------|--------------|----------------|----------------|-----------------|
| Sales | 1,469 | (100%) | 1,999 | (100%) | 36% |
| Cost of sales | -1,082 | (-74%) | -1,515 | (-76%) | 40% |
| Selling | -192 | (-13%) | -241 | (-12%) | 26% |
| G&A | -62 | (-4%) | -71 | (-4%) | 15% |
| R&D | -23 | (-2%) | -26 | (-1%) | 13% |
| EBIT | 84 | (6%) | 97 | (5%) | 15% |
| Net Income (cont.) | 47 | (3%) | 48 | (2%) | 2% |
| EPS pre (cont.) | 1.02 | | 1.05 | | 3% |
| EBITDA | 191 | (13%) | 229 | (11%) | 20% |
| thereof except. | -30 | (-2%) | -24 | (-1%) | -20% |
| EBITDA pre except. | 221 | (15%) | 253 | (12.7%) | 14% |

- Successful pass-through of increased input costs. However, margin impacted by lower utilization and arithmetic effect
- Rising selling expenses result from ongoing higher logistic costs and portfolio effect
- Increase in G&A due to portfolio and FX effect

Q2 2022: Significant sales improvement in all segments




* Total group sales including reconciliation


** Lower result due to hedging and inflated costs due to higher USD

Q2 2022: Strong price-driven growth in all regions

Q2 2022 sales by region [%]



Regional development of sales [€ m]



Improved operating cash flow despite outflow from change in working capital

| [€ m]* | Q2/2021 | Q2/2022 | Δ |
|---|------------|------------|-------------|
| Profit before tax | 67 | 67 | 0 |
| Income taxes paid | -9 | 27 | 36 |
| Changes in other assets and liabilities | -76 | -18 | 58 |
| Oper. CF before Δ in W/C | 100 | 236 | 136 |
| changes in working capital | -99 | -86 | 13 |
| Operating cash flow | 1 | 150 | 149 |
| Investing cash flow | 192 | 47 | -145 |
| thereof capex | -82 | -92 | -10 |
| thereof net invest in money markets | 260 | 134 | -126 |

- Operating cash flow significantly increased
- Continued reimbursement of prepaid taxes
- Factoring of €95 m mitigates outflow from price driven working capital increase
- Change in investing cash flow due to lower net proceeds from money market products

Portfolio and FX effects reflected in balance sheet items

| [€ m] | 31.12.2021 | 30.06.2022 ¹ |
|---------------------------------------|---------------|-------------------------|
| Total assets | 10,518 | 11,820 |
| Equity | 3,762 | 4,517 |
| Equity ratio | 36% | 38% |
| Net financial debt² | 2,245 | 2,547 |
| Liquidity ² | 1,234 | 1,720 |
| Pension provisions | 877 | 461 |
| Net working capital | 1,675 | 1,891 |
| DSI (in days) ³ | 71 | 78 |
| DSO (in days) ³ | 45 | 43 |

- Increase in total assets driven by higher working capital, FX and strengthened liquidity position
- Higher equity reflects positive net income and OCI effects (mainly FX and pensions)
- Higher financial debt due to increased working capital and dividend payment
- Reduced pension provisions due to interest rate increases

¹ BU HPM accounted as “discontinued operations”: Assets & related liabilities of BU HPM summarized in one line item only and no longer included in presented line items (except total assets, equity)

² Including cash, cash equivalents, near cash assets, short-term money market investments

³ Days sales of inventory / sales outstanding calculated from quarterly sales

Housekeeping items 2022


| | |
|---|---|
| Capex 2022 | ~€450 m (incl. IFF MC and excl. HPM D/O) |
| Reconciliation 2022 | ~€180 m – reflecting contribution from BU URE offset by hedging and inflated costs due to higher USD |
| Underlying tax rate | ~28% |
| Exceptionals 2022 | ~€100 m based on current initiatives |
| FX sensitivity | One cent change of USD/EUR resulting in ~€7 m EBITDA pre impact before hedging |
| Book Value BU HPM (30.06.2022) | €1,253 m assets €369 m liabilities |

LANXESS maturity profile actively managed and well balanced

Long-term financing secured

- Diversified financing sources
 - Bonds & private placements
 - Undrawn sustainable revolving credit facility
 - Undrawn committed credit lines
- Average interest rate of financial liabilities ~1.5%
- Maturities in 2022:
 - Bond in November
- All group financing executed without financial covenants

Liquidity and maturity profile as per June 2022




Agenda


- 1 LANXESS today
- 2 Q2 review and financials
- 3 Proactively managing risks**
- 4 Growth opportunities
- 5 Recent portfolio changes

Unprecedented rise in input costs

Sharp increase in raw material costs*




Gas price** as high as never seen before



We are managing inflationary input costs by continuous push for price increases

2022 price increases reflect pass on of raw & energy costs



- Raw material prices are fully forwarded to customers with a typical time lag of one quarter
- Energy prices fully passed on since Q4 2021
- Inflationary environment leads to higher working capital and therefore burdens operating cash flow

Potential gas embargo could be tackled by reduced output of some specific gas intensive plants



Moderate direct impact on major German sites

Situation at sites in North Rhine-Westphalia*:

- Mainly steam and electricity needed for production. Both are based on gas or coal (sourced from CURRENTA)
- LXS / CUR are not directly supplied by Russian gas. However, embargo of Russian gas leads to undersupply in Germany (35-50% sourced from Russia) and would reduce supply of **steam** at LXS sites
- LXS energy costs: only 40% depend on gas in Germany
- Embargo of Russian oil: not an issue

Potential consequences:

- ➔ **Electricity:** Not an issue, replaceable from grid
- ➔ **Steam:** An embargo of Russian gas only leads to a modest direct impact (see following analysis)

Reduced production in 4-5 out of 53 plants could offset Russian gas embargo*


Russian gas embargo should be manageable

| plant | steam demand [t/h] | profitability contribution | necessary action |
|----------|--------------------|----------------------------|---------------------|
| Plant 1 | high | modest | shutdown |
| Plant 2 | high | modest | reduced output |
| Plant 3 | high | modest | reduced output |
| Plant 4 | high | modest | reduced output |
| Plant 5 | medium | modest | reduced output |
| Plant 6 | medium | high | continued operation |
| Plant 7 | medium | high | continued operation |
| | | | continued operation |
| Plant 52 | low | high | continued operation |
| Plant 53 | low | high | continued operation |



Estimated direct EBITDA effect: €80-120 m p.a. – indirect effects not quantifiable

LANXESS manages financial risks proactively and successfully



We are working on all possible levers to improve cash flow

| | 2022 | Following years |
|---------------------|--|---|
| EBITDA pre | <ul style="list-style-type: none"> Contribution from organic growth & acquisitions Higher specialty business due to portfolio optimization | <ul style="list-style-type: none"> Higher margin business |
| Exceptionals | <ul style="list-style-type: none"> Lower M&A activity Less cost for digitalization & restructuring | <ul style="list-style-type: none"> Further reduction |
| WC | <ul style="list-style-type: none"> Release once input costs normalize | <ul style="list-style-type: none"> Inflow, Disciplined WC management |
| CAPEX | <ul style="list-style-type: none"> Reflecting HPM carve out | <ul style="list-style-type: none"> Prudent CAPEX spending |

Multiple levers over mid-term to improve cashflow

Agenda




- 1 LANXESS today
- 2 Q2 review and financials
- 3 Proactively managing risks
- 4 **Growth opportunities**
- 5 Recent portfolio changes




EU market for battery chemicals to grow to over EUR 10 billion by 2025

Massive growth in demand for battery cells in the EU

Chemistry accounts for 2/3 of battery cell costs



LANXESS offers key products for Li-Ion batteries



Battery housing

- PA/PBT compounds for components of the e-powertrain (BU HPM)

Electrolyte

- Key materials (Hydrofluoric acid, phosphorus chemicals) for electrolyte salt (LiPF_6) (BU AII/BU PLA)
- Flame retardants (BU PLA)

Cathode & Anode

- Iron oxide as precursor for cathode active materials (BU IPG)
- Ion-exchange resins for refining battery grade cobalt, nickel and lithium (BU LPT)
- Lithium chemicals from tail-brine (BU PLA)*


LANXESS starts electrolyte production for Li-Ion batteries in cooperation with market leader TINCI



Partnership with TINCI


- TINCI (Chinese Guangzhou Tinci Materials): a leading manufacturer for battery materials and the largest electrolyte producer worldwide
- Saltigo starts electrolyte production for TINCI in its high-tech plant in Leverkusen (Germany) early 2022

TINCI with leading position in fragmented electrolyte market*




Local raw material supply is key for cell manufacturers and OEMs

Digital trading at CheMondis is booming – first online marketplace for Chemicals



CheMondis

- B2B platform for chemical products
- Profound chemical expertise, high technological skillset
- Clear customer and market focus
- CheMondis operates fully independent with own organization, own systems and own market presence





Agenda

- 1 LANXESS today
- 2 Q2 review and financials
- 3 Proactively managing risks
- 4 Growth opportunities
- 5 Recent portfolio changes

Improving our financial profile via active portfolio management


Track record of successful M&A transactions (selc.)

Increasing true specialty nature of portfolio



— = LXS product portfolio

Formation of a powerful plastics JV - immediate cash-in and clear exit determined





- Immediate cash-in of at least €1.1 bn
- LANXESS has exit possibility:
 - Earliest exit possibility after 3 years
 - Fixed multiple for complete exit offers upside due to synergies
- Closing & deconsolidation of BU HPM expected H1 2023*

LANXESS retains exit option for ≤40% ownership in JV

HPM & DEM: Bringing together two strong global Engineering materials players




| |  High Performance Materials |  Engineering Materials | Combined KPI in JV |
|-------------------------|--|---|---------------------------|
| Sales | ~€1.5 bn | ~€1.5 bn | ~€3.0 bn |
| EBITDA pre | ~€210 m | ~€300 m | € ~510 m plus synergies |
| Production sites | 10 | 8 | 18 |
| R&D centers | 7 | 7 | 14 |
| Employees | ~1,900 | ~2,100 | ~4,000 |

LANXESS to own ≤40% in Joint Venture with combined EBITDA: ~€510 m plus synergies

Combining HPM & DEM offers massive synergy potential




Synergies based on highly complementary businesses



- Portfolio combinations
- Overlap of HPM with DEM Specialty business (Procurement, compounding)
- Cross-Selling
- Optimization of PA6 Polymerization in EMEA




Use of proceeds in line with capital markets' interests




Transaction strengthens balance sheet and creates options for shareholder return

Financials: Enhancing MPP's strong financial profile



Investment criteria met



Targeting €30m synergies, thereof €25m by 2024



Top line synergies: ~ €10m

- Complementary geographies and customers
- Cross selling potential
- New applications: energy market and hygiene




Cost synergies: ~ €20m

- Streamlining of sales office infrastructure
- Optimization of supply chain and distribution model
- Sourcing synergies
- Manufacturing excellence


Substantial synergies

Illustrative




| | 2022 | 2023 | 2024 | 2025 |
|------------------|--------|--------|--------|-------|
| Synergies | ~ €5m | ~ €10m | ~ €10m | ~ €5m |
| OTCs | ~ €15m | ~ €10m | ~ €5m | - |
| CAPEX* | ~ €10m | ~ €5m | ~ €5m | - |

BU F&F Financials: Reflecting specialty character



Investment criteria met



Emerald Kalama Chemical acquisition: Synergies, OTCs and Capex step in earlier than expected




Overview: Synergies structure

Phasing: Synergies, OTCs and CAPEX

Illustrative

Top line synergies



Cost based synergies

update

| | 2021 | 2022 | 2023 | 2024 |
|------------------|--------|--------|--------|--------|
| Synergies | <€5 m | ~€10 m | ~€5 m | ~€5 m |
| OTCs | ~€15 m | ~€10 m | ~€5 m | ~€5 m |
| CAPEX* | ~€15 m | ~€15 m | ~€15 m | ~€10 m |

Contact details Investor Relations



Oliver Stratmann
Head of Treasury & Investor Relations

Tel.: +49 221 8885 9611
Fax.: +49 221 8885 4944
Mob.: +49 175 304 9611
E-Mail: oliver.stratmann@lanxess.com



André Simon
Head of Investor Relations

Tel.: +49 221 8885 3494
Fax.: +49 221 8885 4944
Mob.: +49 175 302 3494
E-Mail: andre.simon@lanxess.com




Lisa Häckel
Investor Relations Assistant

Tel.: +49 221 8885 9834
Fax.: +49 221 8885 4944
Mob.: +49 151 7461 4637
E-Mail: lisa.haeckel@lanxess.com



Visit the IR website



Eva Frerker
Institutional Investors / Analysts

Tel.: +49 221 8885 5249
Fax.: +49 221 8885 4944
Mob.: +49 151 7461 2969
E-Mail: eva.frerker@lanxess.com



Anja K. Siehler
Institutional Investors / Analysts

Tel.: +49 221 8885 1035
Fax.: +49 221 8885 4944
Mob.: +49 151 7461 2789
E-Mail: anja.siehler@lanxess.com



Markus Sieben
Institutional Investors / Analysts

Tel.: +49 221 8885 7344
Fax.: +49 221 8885 4944
Mob.: +49 151 7461 2913
E-Mail: markus.sieben@lanxess.com



Mirjam Reetz
ESG & Retail Investors

Tel.: +49 221 8885 1272
Fax.: +49 221 8885 4944
Mob.: +49 151 7461 3158
E-Mail: mirjam.reetz@lanxess.com

Abbreviations



Advanced Intermediates

| | |
|------------|-----------------------------------|
| AI | Advanced Industrial Intermediates |
| IPG | Inorganic Pigments |



Consumer Protection

| | |
|----------------|----------------------------------|
| F&F | Flavors & Fragrances |
| LPT | Liquid Purification Technologies |
| MPP | Material Protection Products |
| SGO | Saltigo |



Specialty Additives

| | |
|------------|------------------------------|
| LAB | Lubricant Additives Business |
| PLA | Polymer Additives |
| RCH | Rhein Chemie |

LANXESS
Energizing Chemistry